Adam J Nelson1, Kevin Haynes2, Sonali Shambhu2, Zubin Eapen3, Mark J Cziraky2, Michael G Nanna4, Sara B Calvert5, Kerrin Gallagher2, Neha J Pagidipati1, Christopher B Granger6. 1. Duke Clinical Research Institute, Durham, North Carolina, USA. 2. HealthCore, Wilmington, Delaware, USA. 3. Element Science, San Francisco, California, USA. 4. Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA. 5. Duke Clinical Research Institute, Durham, North Carolina, USA; Clinical Trials Transformation Initiative, Durham, North Carolina, USA. 6. Duke Clinical Research Institute, Durham, North Carolina, USA. Electronic address: christopher.granger@duke.edu.
Abstract
BACKGROUND: Preventive therapy among patients with established atherosclerotic cardiovascular disease (ASCVD) is generally underused. Whether new guideline recommendations and a focus on implementation have improved the use of high-intensity statins is unknown. OBJECTIVES: This study sought to evaluate the patterns and predictors of statin use among patients with ASCVD. METHODS: In this retrospective cohort study, pharmacy and medical claims data from a commercial health plan were queried for patients with established ASCVD between January 31, 2018, and January 31, 2019. Statin use on an index date of January 31, 2019, was evaluated, as was 12-month adherence and discontinuation. Multivariable logistic regression was used to determine independent associations with statin use of varying intensities. RESULTS: Of the 601,934 patients with established ASCVD, 41.7% were female, and the mean age was 67.5 ± 13.3 years. Overall, 22.5% of the cohort were on a high-intensity statin, 27.6% were on a low- or moderate-intensity statin, and 49.9% were not on any statin. In multivariable analysis, younger patients, female patients, and those with higher Charlson comorbidity score were less likely to be prescribed any statin. Among statin users, female patients, older patients, and those with peripheral artery disease were less likely to be on a high-intensity formulation, whereas a cardiology encounter in the prior year increased the odds. The majority of high-intensity stain users achieved high levels of adherence. CONCLUSIONS: Substantial underuse of statins persists in a large, insured, and contemporary cohort of patients with ASCVD from the United States. In particular, concerning gaps in appropriate statin use remain among younger patients, women, and those with noncoronary ASCVD.
BACKGROUND: Preventive therapy among patients with established atherosclerotic cardiovascular disease (ASCVD) is generally underused. Whether new guideline recommendations and a focus on implementation have improved the use of high-intensity statins is unknown. OBJECTIVES: This study sought to evaluate the patterns and predictors of statin use among patients with ASCVD. METHODS: In this retrospective cohort study, pharmacy and medical claims data from a commercial health plan were queried for patients with established ASCVD between January 31, 2018, and January 31, 2019. Statin use on an index date of January 31, 2019, was evaluated, as was 12-month adherence and discontinuation. Multivariable logistic regression was used to determine independent associations with statin use of varying intensities. RESULTS: Of the 601,934 patients with established ASCVD, 41.7% were female, and the mean age was 67.5 ± 13.3 years. Overall, 22.5% of the cohort were on a high-intensity statin, 27.6% were on a low- or moderate-intensity statin, and 49.9% were not on any statin. In multivariable analysis, younger patients, female patients, and those with higher Charlson comorbidity score were less likely to be prescribed any statin. Among statin users, female patients, older patients, and those with peripheral artery disease were less likely to be on a high-intensity formulation, whereas a cardiology encounter in the prior year increased the odds. The majority of high-intensity stain users achieved high levels of adherence. CONCLUSIONS: Substantial underuse of statins persists in a large, insured, and contemporary cohort of patients with ASCVD from the United States. In particular, concerning gaps in appropriate statin use remain among younger patients, women, and those with noncoronary ASCVD.
Authors: Wiley V Chan; Thomas A Pearson; Glen C Bennett; William C Cushman; Thomas A Gaziano; Paul N Gorman; Joel Handler; Harlan M Krumholz; Robert F Kushner; Thomas D MacKenzie; Ralph L Sacco; Sidney C Smith; Victor J Stevens; Barbara L Wells Journal: J Am Coll Cardiol Date: 2017-01-26 Impact factor: 24.094
Authors: Quynh A Truong; Sabina A Murphy; Carolyn H McCabe; Annemarie Armani; Christopher P Cannon Journal: Circ Cardiovasc Qual Outcomes Date: 2011-04-12
Authors: Michael G Nanna; Ann Marie Navar; Tracy Y Wang; Shuang Li; Salim S Virani; Zhuokai Li; Jennifer G Robinson; Veronique L Roger; Peter W F Wilson; Anne C Goldberg; Andrew Koren; Michael J Louie; Eric D Peterson Journal: Am Heart J Date: 2019-05-22 Impact factor: 4.749
Authors: Rory Collins; Christina Reith; Jonathan Emberson; Jane Armitage; Colin Baigent; Lisa Blackwell; Roger Blumenthal; John Danesh; George Davey Smith; David DeMets; Stephen Evans; Malcolm Law; Stephen MacMahon; Seth Martin; Bruce Neal; Neil Poulter; David Preiss; Paul Ridker; Ian Roberts; Anthony Rodgers; Peter Sandercock; Kenneth Schulz; Peter Sever; John Simes; Liam Smeeth; Nicholas Wald; Salim Yusuf; Richard Peto Journal: Lancet Date: 2016-09-08 Impact factor: 79.321
Authors: Shipra Arya; Anjali Khakharia; Zachary O Binney; Randall R DeMartino; Luke P Brewster; Philip P Goodney; Peter W F Wilson Journal: Circulation Date: 2018-01-12 Impact factor: 29.690
Authors: Angela Lowenstern; Shuang Li; Ann Marie Navar; Salim Virani; L Veronica Lee; Michael J Louie; Eric D Peterson; Tracy Y Wang Journal: Am Heart J Date: 2018-03-24 Impact factor: 4.749
Authors: Frances A Wood; James P Howard; Judith A Finegold; Alexandra N Nowbar; David M Thompson; Ahran D Arnold; Christopher A Rajkumar; Susan Connolly; Jaimini Cegla; Chris Stride; Peter Sever; Christine Norton; Simon A M Thom; Matthew J Shun-Shin; Darrel P Francis Journal: N Engl J Med Date: 2020-11-15 Impact factor: 91.245
Authors: Benjamin M Scirica; Christopher P Cannon; Naomi D L Fisher; Thomas A Gaziano; David Zelle; Kira Chaney; Angela Miller; Hunter Nichols; Lina Matta; William J Gordon; Shawn Murphy; Kavi B Wagholikar; Jorge Plutzky; Calum A MacRae Journal: Circulation Date: 2020-11-17 Impact factor: 29.690